Low-grade oligodendroglioma: Current treatments and future hopes

Expert Review of Anticancer Therapy

Volumn 9, Issue 11, 2009, Pages 1651-1661

  Lwin, Zarnie ^b   Gan, Hui K ^b   Mason, Warren P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Chemotherapy; Gliomas; Molecular predictors of response; Oligoastrocytomas; Oligodendrogliomas; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER GENETICS; CANCER GRADING; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CLINICAL TRIAL; DRUG MECHANISM; GENETIC DISTANCE; HISTOPATHOLOGY; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PATIENT SAFETY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RECURRENT CANCER; REVIEW; STEREOTAXIC SURGERY; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTOMA; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; OLIGODENDROGLIOMA; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT;

EID: 71949102846     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.127     Document Type: Review

References (90)

1. Mason WP, Cairncross JG. The expanding impact of molecular biology on the diagnosis and treatment of gliomas. Neurology 71, 365-373 (2008).
2. Kleihues P, Cavanee W. Pathology and Genetics of Tumours of the Nervous System. IARC Press, Lyon, France (2000).
3. Walker DG, Kaye AH. Low grade glial neoplasms. J. Clin. Neurosci. 10(1), 1-13 (2003).
4. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 352(10), 987-996 (2005). •• Established concurrent chemoradiotherapy with temozolomide as the standard of care for newly diagnosed patients with glioblastoma multiforme.
5. Agulnik M, Mason WP. The changing management of low-grade astrocytomas and oligodendrogliomas. Hematol. Oncol. Clin. North Am. 20(6), 1249-1266 (2006). (Pubitemid 44739213)
6. Ashby LS, Shapiro WR. Low-grade glioma: supratentorial astrocytoma, oligodendroglioma, and oligoastrocytoma in adults. Curr. Neurol. Neurosci. Rep. 4(3), 211-217 (2004).
7. Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54(7), 1442-1448 (2000). (Pubitemid 30210463)
8. Lebrun C, Fontaine D, Ramaioli A et al. Long-term outcome of oligodendrogliomas. Neurology 62(10), 1783-1787 (2004).
9. Kleihues P, Louis DN, Scheithauer BW et al. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 61(3), 215-225 (2002). (Pubitemid 34212595)
10. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79(7), 1381-1393 (1997).
11. Sepulveda Sanchez JM, Martinez Montero JC, Diez-Lobato R et al. Classification of oligodendroglial tumors based on histopathology criteria is a significant predictor of survival - clinical, radiological and pathologic long-term follow-up analysis. Clin. Neuropathol. 28(1), 11-20 (2009).
12. Hart MN, Petito CK, Earle KM. Mixed gliomas. Cancer 33, 134-140 (1974).
13. Kim L, Hochberg FH, Thornton AF et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J. Neurosurg. 85(4), 602-607 (1996). (Pubitemid 26315193)
14. Mork S, Halvorsen T, Lindegaard K, Eide G. Oligodendroglioma. Histologic evaluation and prognosis. J. Neuropathol. Exp. Neurol. (45), 65-78 (1986).
15. Mork SJ, Lindegaard KF, Halvorsen TB et al. Oligodendroglioma: incidence and biological behavior in a defined population. J. Neurosurg. 63(6), 881-889 (1985).
16. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am. J. Pathol. 145(5), 1175-1190 (1994). (Pubitemid 24345665)
17. Iwamoto FM, Nicolardi L, Demopoulos A et al. Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J. Neurooncol. 88(3), 293-298 (2008).
18. Walker C, du Plessis DG, Fildes D et al. Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin. Cancer Res. 10(21), 7182-7191 (2004). (Pubitemid 39487704)
19. Adamson DC, Broderick DK, Di C et al. Genetic analysis of LOH of chromosome 1p, 19q and PIK3CA mutations in oligodendrogliomas. AACR Meeting Abstracts 2005(1), D659-D660 (2005).
20. Chan R, Kocialkowski S, Pearson D, Collins VP, Ichimura K. High resolution array-CGH reveals novel homozygous deletions at PTPRD in oligodendrogliomas. AACR Meeting Abstracts (2008) (Abstract 1684).
21. Walker C, Haylock B, Husband D et al. Molecular genetics and response to PCV chemotherapy in previously untreated oligodendroglial neoplasms. AACR Meeting Abstracts 2005(1), (2005) (Abstract 507).
22. Buckner JC, Ballman KV, Scheithauer BW et al. NCCTG 94-72-53: diagnostic and prognostic significance of 1p and 19q deletions in patients (pts) with low-grade oligodendroglioma and astrocytoma. J. Clin. Oncol. 23(16 Suppl.), (2005) (Abstract 1502).
23. Jenkins RB, Blair H, Ballman KV et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 66(20), 9852-9861 (2006). •• Elucidates the mechanism underlying the high frequency of simultaneous 1p and 19q deletions. (Pubitemid 44672036)
24. Bagchi A, Papazoglu C, Francis D, Bradley A, Mills AA. Identification and functional characterization of a novel tumor suppressor region at human 1p36. AACR Meeting Abstracts (1), (2006) (Abstract C609).
25. Dunlap SM, McDonald JM, Fuller GN et al. The putative tumor suppressor Shrew-1 gene on chromosome 1p36 inhibits adhesion and migration of glioma cells. AACR Meeting Abstracts 2005(1), (2005) (Abstract A680).
26. Walker C, du Plessis DG, Joyce KA et al. Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann. Neurol. 57(6), 855-865 (2005).
27. Campbell B, Horsman D, Maguire J et al. Chromosomal alterations in oligodendroglial tumors over multiple surgeries: is progression associated with change in 1p/19q status? J. Clin. Oncol. 25(18 Suppl.), (2007) (Abstract 10577).
28. Johnson NV, Connelly JJ, Virigadamo J et al. Characterizing oligodendroglioma rearrangements using whole genome hrCGH arrays. AACR Meeting Abstracts 2006(1), (2006) (Abstract B36).
29. Holmes K, Dunlap S, Cogdell D, Chow C-W, Fuller G, Zhang W. Integrin-linked kinase contributes to glioma progression in a glial-specific transgenic mouse model. AACR Meeting Abstracts (2008) (Abstract 2909).
30. Dunlap S, Holmes K, Cogdell D, Chow C-W, Fuller G, Zhang W. Integrin binding is essential for IGFBP2-driven glioma progression. AACR Meeting Abstracts (2008) (Abstract 1969).
31. Dong SM, Pang JC, Poon WS et al. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J. Neuropathol. Exp. Neurol. 60(8), 808-816 (2001).
32. Mollemann M, Wolter M, Felsberg J et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int. J. Cancer 113(3), 379-385 (2005). (Pubitemid 40038704)
33. Brandes AA, Tosoni A, Cavallo G et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J. Clin. Oncol. 24(29), 4746-4753 (2006). (Pubitemid 46630938)
34. Mikkelsen T, Doyle T, Anderson J et al. Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J. Neurooncol. 92(1), 57-63 (2009).
35. Vogelbaum MA, Berkey B, Peereboom D et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol. 11(2), 167-175 (2009).
36. Nicolardi L, Bertorelle R, Bonaldi L et al. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and relation to 1p/19q loss in low grade gliomas: A GICNO study. J. Clin. Oncol. 24(18 Suppl.), (2006) (Abstract 20064).
37. Wick Wolfgang W, Weller M. Randomized Phase III study of sequential radiochemotherapy of oligoastrocytic tumors of WHO-grade III with PCV or temozolomide: NOA-04. J. Clin. Oncol. 26(15 Suppl.), (2008) (Abstract LBA2007).
38. Hegi ME, Liu L, Herman JG et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol. 26(25), 4189-4199 (2008).
39. Hegi ME, Diserens A-C, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005). •• Identifies the importance of MGMT promoter methylation as a predictor of clinical outcomes in patients with glioblastoma receiving temozolomide therapy.
40. Ashby LS, Pueschel JK, Scheck AC, Coons SW, Shapiro WR. Prognostic factors for patients with newly diagnosed low-grade oligodendroglial tumors: molecular genetics, histopathology, and neuroimaging. J. Clin. Oncol. 23(16 Suppl.), (2005) (Abstract 1501).
41. Prayson RA, Castilla EA, Hembury TA, Liu W, Noga CM, Prok AL. Interobserver variability in determining MIB-1 labeling indices in oligodendrogliomas. Ann. Diagn. Pathol. 7(1), 9-13 (2003). (Pubitemid 36292644)
42. Maiuri F, Del Basso De Caro ML, Iaconetta G, Peca C, Esposito M, de Divitiis E. Prognostic and survivalrelated factors in patients with welldifferentiated oligodendrogliomas. Zentralbl. Neurochir. 67(4), 204-209 (2006). (Pubitemid 44951682)
43. Van den Bent MJ, Reni M, Gatta G, Vecht C. Oligodendroglioma. Crit. Rev. Oncol. Hematol. 66(3), 262-272 (2008).
44. Cairncross G, Berkey B, Shaw E et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group trial 9402. J. Clin. Oncol. 24(18), 2707-2714 (2006). •• Clarifies the role of adjuvant chemotherapy in patients with anaplastic gliomas and shows that 1p/19q codeletions are prognostic rather than predictive factors.
45. van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer Phase III trial. J. Clin. Oncol. 24(18), 2715-2722 (2006). •• Clarifies the role of adjuvant chemotherapy in patients with anaplastic gliomas and shows that 1p/19q codeletions are prognostic rather than predictive factors.
46. Soffietti R, Ruda R, Trevisan E et al. Temozolomide (TMZ) 1 week on/1 week off as initial treatment for progressive low grade oligodendroglial tumors: a Phase II AINO study. J. Clin. Oncol. 26(15 Suppl.), (2008) (Abstract 2019).
47. El-Hateer H, Souhami L, Roberge D et al. Low-grade oligodendroglioma: an indolent but incurable disease? J. Neurosurg. 111(2), 265-271 (2009).
48. The German Glioma Network, Weller M, Berger H et al. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin. Cancer Res. 13(23), 6933-6937 (2007).
49. Okamoto Y, Di Patre P, Burkhard C, Horstmann S, Jourde B, Fahey M. Population based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 108, 49-56 (2004). (Pubitemid 38961073)
50. See S-J, Gilbert MR. Chemotherapy in adults with gliomas. Ann. Acad. Med. Singapore 36(5), 364-366 (2007).
51. Law M, Oh S, Johnson G et al. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 58(6), 1099-1107 (2006). (Pubitemid 43879544)
52. Brown R, Zlatescu M, Sijben A et al. The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin. Cancer Res. 14(8), 2357-2362 (2008). (Pubitemid 351551068)
53. Norden AD, Wen PY. Glioma therapy in adults. Neurologist 12(6), 279-292 (2006).
54. Lang FF, Gilbert MR. Diffusely infiltrative low-grade gliomas in adults. J. Clin. Oncol. 24(8), 1236-1245 (2006).
55. Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J. Neurosurg. 95(5), 735-745 (2001).
56. Leighton C, Fisher B, Bauman G et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J. Clin. Oncol. 15(4), 1294-1301 (1997). (Pubitemid 27167360)
57. Claus EB, Horlacher A, Hsu L et al. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer 103(6), 1227-1233 (2005). (Pubitemid 40328094)
58. Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74(6), 1784-1791 (1994). (Pubitemid 24301834)
59. Smith JS, Chang EF, Lamborn KR et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J. Clin. Oncol. 26(8), 1338-1345 (2008).
60. Scerrati M, Roselli R, Iacoangeli M. Prognostic factors in low-grade WHO grade II gliomas of cerebral hemispheres: the role of surgery. J. Neurol. Neurosurg. Psychiatry, (61), 291-296 (1996). (Pubitemid 26293725)
61. Chaichana KL, McGirt MJ, Laterra J, Olivi A, Quiñones-Hinojosa A. Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J. Neurosurg. DOI: 10.3171/2008.10.JNS08608 (2009) (Epub ahead of print).
62. Shaw EG. The low-grade glioma debate: evidence defending the position of early radiation therapy. Clin. Neurosurg. 42, 488-494 (1995).
63. Mason WP. Progress in clinical neurosciences: advances in the management of low-grade gliomas. Can. J. Neurol. Sci. 32(1), 18-26 (2005).
64. Kortmann R-D. Radiotherapy in low-grade gliomas: pros. Semin. Oncol. 30(Suppl. 19), 29-33 (2003).
65. Engelhard HH. Current diagnosis and treatment of oligodendroglioma. Neurosurg. Focus 12(2), E2 (2002).
66. Stieber VW. Low-grade gliomas. Curr. Treat. Options Oncol. 2(6), 495-506 (2001).
67. Surma-aho O, Niemela M, Vilkki J et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 56(10), 1285-1290 (2001). (Pubitemid 32455284)
68. Douw L, Klein M, Fagel SS et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 8(9), 810-818 (2009).
69. Karim AB, Afra D, Cornu P et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer study 22845 with the Medical Research Council study BRO4: an interim analysis. Int. J. Radiat. Oncol. Biol. Phys. 52(2), 316-324 (2002). •• Demonstrated that progression-free survival is improved with immediate rather than delayed radiotherapy after surgical resection.
70. Fisher B, Leighton C, Macdonald D, Stitt L, Bauman G, Cairncross G. The dose-volume interaction in adult supratentorial low-grade glioma: higher radiation dose is beneficial among patients with partial resection. J. Neurooncol. 82, 165-170 (2007). (Pubitemid 46431859)
71. Karim AB, Maat B, Hatlevoll R et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int. J. Radiat. Oncol. Biol. Phys. 36(3), 549-556 (1996). (Pubitemid 26404297)
72. Shaw E, Arusell R, Scheithauer B et al. Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment group/Radiation Therapy Oncology group/Eastern Cooperative Oncology group study. J. Clin. Oncol. 20(9), 2267-2276 (2002). (Pubitemid 34441653)
73. Smith JS, Chang EF, Lamborn KR et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J. Clin. Oncol. 26(8), 1338-1345 (2008).
74. Jeremic B, Milicic B, Grujicic D et al. Hyperfractionated radiation therapy for incompletely resected supratentorial low-grade glioma: a 10 year update of a Phase II study. Int. J. Radiat. Oncol. Biol. Phys. 57, 465-471 (2003). (Pubitemid 37040943)
75. van den Bent MJ. Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies. Semin. Oncol. 30(Suppl. 19), 39-44 (2003).
76. Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology 46(1), 203-207 (1996). • Establishes the chemoresponsive nature of low-grade oligodendrogliomas.
77. Eyre HJ, Crowley JJ, Townsend JJ et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J. Neurosurg. 78(6), 909-914 (1993).
78. Buckner JC, Gesme D Jr, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J. Clin. Oncol. 21(2), 251-255 (2003).
79. Shaw EG, Wang M, Coons S et al. Final report of radiation therapy oncology group (RTOG) protocol 9802: radiation therapy (RT) versus RT + procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). J. Clin. Oncol. 26(15 Suppl.), (2008) (Abstract 2006).
80. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int. J. Cancer 113(3), 379-385 (2005). (Pubitemid 40038704)
81. Lesser GJ. Chemotherapy of low-grade gliomas. Semin. Radiat. Oncol. 11(2), 138-144 (2001).
82. van den Bent MJ. Chemotherapy of oligodendroglial tumours: current developments. Forum Trends Exp. Clin. Med. 10(2), 108-118 (2000).
83. van den Bent MJ, Hegi ME, Stupp R. Recent developments in the use of chemotherapy in brain tumours. Eur. J. Cancer 42(5), 582-588 (2006). (Pubitemid 43343679)
84. Brada M, Viviers L, Abson C et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann. Oncol. 14(12), 1715-1721 (2003). (Pubitemid 38029041)
85. Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J. Clin. Oncol. 22(15), 3133-3138 (2004). (Pubitemid 41103727)
86. Pace A, Vidiri A, Galie E et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann. Oncol. 14(12), 1722-1726 (2003). (Pubitemid 38029042)
87. Quinn JA, Reardon DA, Friedman AH et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J. Clin. Oncol. 21(4), 646-651 (2003).
88. Kesari S, Schiff D, Drappatz J et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin. Cancer Res. 15(1), 330-337 (2009).
89. Pouratian N, Gasco J, Sherman J, Shaffrey M, Schiff D. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J. Neurooncol. 82(3), 281-288 (2007). (Pubitemid 46614391)
90. Schiff D, Brown PD, Giannini C. Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 69(13), 1366-1373 (2007). (Pubitemid 47482451)